Literature DB >> 30291490

Immunomodulatory properties of captopril, an ACE inhibitor, on LPS-induced lung inflammation and fibrosis as well as oxidative stress.

Javad Boskabadi1,2, Vahid Reza Askari1,3,4, Mahmoud Hosseini5,6, Mohammad Hossein Boskabady7,8.   

Abstract

BACKGROUND: The role of angiotensin converting enzyme inhibitors on the inflammation process has been demonstrated previously. In the present study, the effects of captopril on lung injury induced by lipopolysaccharide (LPS) were investigated.
METHODS: Control, LPS, 12.5, 25 and 50 mg/kg captopril-treated before LPS administration and captopril 50 mg/kg before saline administration groups of rats were studied. Total and percentage of differential WBC, the levels of MDA, total thiol groups, the activities of SOD and CAT, the levels of IFN-γ, PGE2, TGF-β1 and IL-4 in the BALF were evaluated.
RESULTS: MDA concentration in LPS groups treated with all captopril concentrations, total WBC in LPS + Cap50, percent of neutrophils in LPS + Cap25 and LPS + Cap50, levels of IFN-γ, PGE2, TGF-β1 in LPS + Cap50 and IFN-γ/IL-4 ratio in LPS + Cap25 and LPS + Cap50 were significantly decreased but total thiol groups and activity of SOD in LPS + Cap25 and LPS + Cap50, percent of lymphocyte, CAT activity and concentration of IL-4 only in LPS + Cap50 group were increased in comparison to the LPS group (p < 0.05 to p < 0.001).
CONCLUSION: Captopril dose dependently improved oxidant-antioxidant biomarkers, the imbalance between pro-inflammatory and anti-inflammatory cytokines and showed specific immunomodulatory effect on Th1/Th2 balance in the BALF of lung injury induced by LPS.

Entities:  

Keywords:  Captopril; Cytokines; Inflammation; LPS; Lung; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30291490     DOI: 10.1007/s10787-018-0535-4

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  10 in total

1.  [Association of age distribution with the expression of angiotensin-converting enzyme 2 in lung tissues in severe acute respiratory syndrome coronavirus 2 infection: reflections from the study of RAS pathway expression in mice].

Authors:  Li-Li Lou; Liang Xie; Yu Hu; Li-Na Chen; Ping Liang; Fang Shi; Cai-Jun Liu; Han-Min Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-10

Review 2.  A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-05-22       Impact factor: 8.739

Review 3.  COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?

Authors:  T Filardi; S Morano
Journal:  J Endocrinol Invest       Date:  2020-06-03       Impact factor: 4.256

4.  Comparison of Th1/Th2 and Treg/Th17 ratios between wet and dry cupping therapies in Persian medicine.

Authors:  Reza Soleimani; Mojgan Mohammadi; Seyed Ahmad Saghebi; Ali Taghipour; Ali Khorsand Vakilzadeh; Jalil Tavakkol Afshari
Journal:  Avicenna J Phytomed       Date:  2020 Jan-Feb

5.  Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

6.  Anti-Inflammatory Activities of Captopril and Diuretics on Macrophage Activity in Mouse Humoral Immune Response.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

7.  Captopril alleviates epilepsy and cognitive impairment by attenuation of C3-mediated inflammation and synaptic phagocytosis.

Authors:  Xinyan Dong; Jianchen Fan; Donghui Lin; Xuehui Wang; Haoyu Kuang; Lifen Gong; Chen Chen; Jie Jiang; Ningxiao Xia; Dahong He; Weida Shen; Peifang Jiang; Rong Kuang; Linghui Zeng; Yicheng Xie
Journal:  J Neuroinflammation       Date:  2022-09-14       Impact factor: 9.587

8.  Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.

Authors:  Reinhold Kreutz; Engi Abd El-Hady Algharably; Michel Azizi; Piotr Dobrowolski; Tomasz Guzik; Andrzej Januszewicz; Alexandre Persu; Aleksander Prejbisz; Thomas Günther Riemer; Ji-Guang Wang; Michel Burnier
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

Review 9.  Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019.

Authors:  Wenyi Peng; Hao Wu; Yan Tan; Mei Li; Dachun Yang; Shuang Li
Journal:  Life Sci       Date:  2020-09-25       Impact factor: 5.037

10.  The angiotensin-converting enzyme inhibitor, captopril, suppressed hepatic stellate cell activation via NF-kappaB or wnt3α/β-catenin pathway.

Authors:  Zhaodi Gu; Linjun Fang; Peijun Ma
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.